1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Abliva AB (publ)

Abliva AB (publ)

NEVPF
Abliva AB (publ)US flagOther OTC
0.03
USD
- -
- -
45.13MMarket Cap
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
TTM
Revenue per Share
- -
0.21
0.21
0.06
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-0.64
-0.87
-1.23
-2.32
-1.32
-1.17
-0.85
-0.44
-0.23
-0.33
-0.12
-0.09
-0.07
-0.07
Free Cash Flow per Basic Share
-0.94
-1.2
-1.94
-2.34
-1.42
-1.1
-0.84
-0.43
-0.27
-0.31
-0.22
-0.01
-0.08
-0.08
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-1.46
-2.19
-3.02
-5.01
-4.96
-5.75
-4.89
-2.65
-2.23
-1.86
-1
-0.79
-0.66
-0.67
Tangible Book Value per Share
1.3
1.08
0.82
2.06
1.83
0.55
0.29
0.3
0.26
0.05
0.2
0.06
0.04
0.04
Basic Weighted Avg Shares
23
26
35
39
53
57
80
176
257
370
739
1,056
1,351
1,335
Sales/Revenue/Turnover
- -
5
7
3
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
-418.86
-621.87
-2,487.85
-361,214.29
-223,451.85
-1,451,420
-57,276.12
-27,858.33
-81,557.62
-273,887.1
-71,454.74
- -
- -
Depreciation Expense
- -
- -
- -
1
1
2
2
2
3
3
3
10
2
2
Net Income, GAAP
-15
-22
-43
-90
-70
-67
-68
-77
-60
-123
-85
-96
-90
-90
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
-418.58
-594.92
-3,601.88
-501,721.43
-247,140.74
-1,367,460
-57,458.21
-27,772.69
-81,782.78
-275,038.71
-69,714.6
- -
- -
Working Capital
30
27
28
79
84
18
10
40
53
7
131
46
37
37
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
- -
- -
- -
Total Equity
63
75
108
155
168
106
97
128
89
42
164
71
62
62
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Jun'24
Sep'24
Dec'24
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,349
1,612
1,612
Market Capitalization
- -
124
534

Working Capital

FRC

•

in mil. unless spec.
Jun'24
Sep'24
Dec'24
Total Current Assets
51
72
49
Cash, Cash Equivalents & STI
45
47
33
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
8
9
12
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
18.06%
28.42%
-12.77%
Free Cash Flow
106.86%
209.6%
1,044.16%
Net Income, GAAP
15.88%
11.8%
-5.82%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
-0.05
-0.04
-0.04
- -
-0.12
2023
-0.02
-0.02
-0.03
-0.02
-0.09
2024
-0.02
-0.02
-0.01
-0.02
-0.07

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Ellen K. Donnelly
Full Time Employees
6
Sector
Healthcare
Industry
Biotechnology
Address
Medicon Village Lund Sweden 223 81
IPO Date
Mar 20, 2014
Website
abliva.com
Similar Companies
Aardvark Therapeutics, Inc. Common Stock (AARD)
IntelGenx Technologies Corp. (IGXT)
ArcticZymes Technologies ASA (AZT.OL)
Celcuity Inc. (CELC)
Kexing Biopharm Co., Ltd. (688136.SS)
Oxford Nanopore Technologies plc (ONTTF)
Business
Abliva AB (publ) discovers and develops medicines for the treatment of primary mitochondrial diseases, rare orphan disorders impairing cellular energy production via dysfunctional mitochondria; its lead candidate KL1333, a potent regulator of NAD+ and NADH coenzymes, advances in Phase 2 clinical trials for chronic fatigue and myopathy in genetically confirmed adult patients, while NV354 completes preclinical development targeting mitochondrial disease with neurologic complications; additional programs include NeuroSTAT under license with Owl Therapeutics for traumatic brain injury. Founded in 2000 and headquartered in Lund, Sweden, the company previously operated as NeuroVive Pharmaceutical AB (publ), changing its name to Abliva AB (publ) in May 2020 to reflect its sharpened focus on mitochondrial therapeutics, and maintains operations primarily in Europe with collaborations spanning Asia and North America, including partnerships with Yungjin Pharm for KL1333 clinical development, as well as Isomerase, Children's Hospital of Philadelphia, Newcastle University, University College London, and Oroboros Instruments. In a pivotal strategic shift, Pharming Technologies B.V., a subsidiary of Pharming Group N.V., completed a recommended cash offer in February 2025, acquiring 87.7% of shares at SEK 0.45 per share and all outstanding warrants, followed by plans for compulsory acquisition of remaining shares, delisting from Nasdaq Stockholm, and integration as a fully-owned subsidiary to bolster Pharming's rare disease pipeline with KL1333's U.S. launch potential by 2028 after positive interim Phase 3 analysis in July 2024.

Company News

APIChat

  • defenseworld.net

    Abliva AB (publ) (OTCMKTS:NEVPF) and ProMetic Life Sciences (OTCMKTS:PFSCF) Head to Head Survey